| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Sheena Derry | Q28036347 |
| Robert Andrew Moore | Q56192531 | ||
| Toni Tan | Q114776635 | ||
| P2093 | author name string | Peter Cole | |
| R Andrew Moore | |||
| Andrew Sc Rice | |||
| P2860 | cites work | Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials | Q21261358 |
| Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data | Q21261840 | ||
| Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials | Q21562140 | ||
| The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey | Q21710682 | ||
| Topical lidocaine for neuropathic pain in adults | Q24194814 | ||
| Gabapentin for chronic neuropathic pain and fibromyalgia in adults | Q24194998 | ||
| Topical capsaicin (low concentration) for chronic neuropathic pain in adults | Q24200378 | ||
| Topical capsaicin (high concentration) for chronic neuropathic pain in adults | Q24200709 | ||
| Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Q24201220 | ||
| Amitriptyline for neuropathic pain and fibromyalgia in adults | Q24202439 | ||
| Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews | Q24202563 | ||
| Gabapentin for chronic neuropathic pain and fibromyalgia in adults | Q24235709 | ||
| Pregabalin for acute and chronic pain in adults | Q24239867 | ||
| Topical capsaicin for chronic neuropathic pain in adults | Q24240399 | ||
| Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response | Q24610551 | ||
| Reporting of adverse drug reactions in randomised controlled trials - a systematic survey | Q24805597 | ||
| Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports | Q24816687 | ||
| Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome | Q26826917 | ||
| Influence of trial sample size on treatment effect estimates: meta-epidemiological study | Q27687577 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis | Q28085455 | ||
| Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q28111913 | ||
| Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study | Q28750315 | ||
| Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects | Q29619558 | ||
| Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion | Q40659425 | ||
| How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? | Q43123301 | ||
| NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension | Q43180409 | ||
| NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study | Q43646094 | ||
| The economic impact of chronic pain: a nationwide population-based cost-of-illness study in Portugal | Q44291794 | ||
| Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study | Q45756820 | ||
| Expect analgesic failure; pursue analgesic success | Q45776628 | ||
| Drugs for neuropathic pain. | Q47935094 | ||
| Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey | Q48452749 | ||
| Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice | Q48793362 | ||
| A Multicenter, Randomized, Double-Blind, Controlled Study of NGX-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia | Q50440477 | ||
| Epidemiology and Clinical Features of Idiopathic Trigeminal Neuralgia and Glossopharyngeal Neuralgia: Similarities and Differences, Rochester, Minnesota, 1945-1984 | Q50546491 | ||
| The visual analogue pain intensity scale: what is moderate pain in millimetres? | Q50938732 | ||
| Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. | Q51180087 | ||
| Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. | Q51873580 | ||
| A new definition of neuropathic pain | Q57987223 | ||
| Reporting of Adverse Effects in Clinical Trials Should Be Improved | Q60736688 | ||
| Utility-based outcomes made easy: The number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden | Q60777594 | ||
| A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy | Q82428864 | ||
| Chronic pain: genes, plasticity, and phenotypes | Q82977041 | ||
| Patient-centered perspective on treatment outcomes in chronic pain | Q84517317 | ||
| Individualized pharmacological treatment of neuropathic pain | Q86706388 | ||
| The number needed to treat: a clinically useful measure of treatment effect | Q29619672 | ||
| Meta-analysis in clinical research | Q29620885 | ||
| Systematic review of topical capsaicin for the treatment of chronic pain | Q30829459 | ||
| APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway | Q33328700 | ||
| Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. | Q33332025 | ||
| Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia | Q33715079 | ||
| A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial | Q34301601 | ||
| Prevalence of chronic pain with neuropathic characteristics in the general population. | Q34691911 | ||
| Neuropathic pain: redefinition and a grading system for clinical and research purposes | Q34713765 | ||
| High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know | Q34726023 | ||
| Duloxetine use in chronic painful conditions--individual patient data responder analysis | Q34754874 | ||
| Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy | Q34785640 | ||
| Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary? | Q34805660 | ||
| Incidence of facial pain in the general population | Q35005365 | ||
| Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch | Q35203278 | ||
| Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis | Q36330831 | ||
| An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population | Q36690641 | ||
| Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports | Q36790345 | ||
| Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations | Q37022616 | ||
| A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia | Q37775266 | ||
| GRADE guidelines: 7. Rating the quality of evidence--inconsistency | Q37908778 | ||
| Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses | Q37953039 | ||
| Deconstructing the neuropathic pain phenotype to reveal neural mechanisms | Q37988158 | ||
| GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes | Q38006189 | ||
| GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes | Q38011509 | ||
| The role of the immune system in the generation of neuropathic pain | Q38019775 | ||
| Neuropathic pain needs systematic classification. | Q38075861 | ||
| The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain | Q38086926 | ||
| Neuropathic pain in the general population: a systematic review of epidemiological studies. | Q38167585 | ||
| A Systematic Literature Review And Network Meta-Analysis of Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for The Treatment of Painful Diabetic Peripheral Neuropathy | Q38624459 | ||
| Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain | Q38669012 | ||
| Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study | Q39166037 | ||
| The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study | Q39202304 | ||
| NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials | Q39233673 | ||
| Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports | Q39293222 | ||
| NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study | Q39312497 | ||
| P921 | main subject | neuropathic pain | Q2798704 |
| chronic neuropathic pain | Q58490835 | ||
| P304 | page(s) | CD007393 | |
| P577 | publication date | 2017-01-13 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Topical capsaicin (high concentration) for chronic neuropathic pain in adults | |
| P478 | volume | 1 |
| Q92452018 | A Comprehensive Algorithm for Management of Neuropathic Pain |
| Q94348001 | Antipsychotics for the treatment of neuropathic pain in adults |
| Q56815074 | Cannabis-based medicines for chronic neuropathic pain in adults |
| Q92434547 | Capsaicin: Physicochemical properties, cutaneous reactions and potential applications in painful and inflammatory conditions |
| Q89612411 | Challenges of neuropathic pain: focus on diabetic neuropathy |
| Q64981414 | Chronic postsurgical pain: current evidence for prevention and management. |
| Q92636239 | Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review |
| Q92084348 | Diverse TRPV1 responses to cannabinoids |
| Q64901313 | Essential pharmacologic options for acute pain management in the emergency setting. |
| Q90450609 | Functional and histological improvements of small nerve neuropathy after high-concentration capsaicin patch application: A case study |
| Q34557703 | Gabapentin for chronic neuropathic pain in adults. |
| Q63322122 | Herbal medicinal products or preparations for neuropathic pain |
| Q42736007 | Localized neuropathic pain: an expert consensus on local treatments |
| Q29994484 | Methadone for neuropathic pain in adults |
| Q57488345 | Modalities in managing postherpetic neuralgia |
| Q38771530 | Morphine for chronic neuropathic pain in adults. |
| Q92852084 | Myrcene and terpene regulation of TRPV1 |
| Q64356942 | Pregabalin for neuropathic pain in adults |
| Q38791924 | Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series |
| Q90071281 | The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo |
| Q59797962 | The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomised controlled trials |
| Q92219601 | Therapeutic Approaches for Peripheral and Central Neuropathic Pain |
| Q36369936 | Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. |
| Q61816707 | Topical treatments for diabetic neuropathic pain |
| Q90341000 | [Long-term effectiveness of topical analgesics] |
| Q94563514 | [S2k guideline for the diagnosis and therapy of zoster and post-zoster neuralgia] |
Search more.